These findings were recently confirmed by Garcia et al. [14, 15], who concluded that P-MAPA was responsible for recovering the immunosuppressive microenvironment of bladder cancer than other conventional therapies. This evidence concerns the gene LRRC25 and urinary bladder carcinoma.